Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1

Blood

Volumn 121, Issue 7, 2013, Pages 1229-1237

  Platonova, Natalia ^a,d   Miquel, Geraldine ^a   Regenfuss, Birgit ^b   Taouji, Said ^c   Cursiefen, Claus ^b   Chevet, Eric ^c   Bikfalvi, Andreas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITY OF COLOGNE   (Germany)

^c University of Cologne ^*  (France)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; HYALURONIC ACID; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHO CELL; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMOBILIZATION; LYMPH VESSEL ENDOTHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84874073075     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-450502     Document Type: Article

References (46)

1. Baldwin M, Stacker S, Achen M. Molecular control of lymphangiogenesis. Bio Essays. 2002; 24(11):1030-1040. (Pubitemid 35326161)
2. Cao Y. Angiogenesis and lymphangiogenesis in common diseases. Editorial. Curr Mol Med. 2009; 9(8):928.
3. Alitalo K, Tammela T, Petrova TV. Lymphangio-genesis in development and human disease. Nature. 2005;438(7070):946-953.
4. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J. Comparative evaluation of FGF-2, VEGF-A, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004;94(5):664-670. (Pubitemid 38387750)
5. Cao Y, Zhong W. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Phar-macother. 2007;61(9):534-539. (Pubitemid 47562689)
6. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005;5(9):735-43. (Pubitemid 41486366)
7. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF2 for lymphan-giogenesis. Proc Natl Acad Sci USA. 2004; 101(32):11658-11663.
8. Shin JW, Min M, Larrieu-Lahargue F, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endo-thelium: a role for FGF signaling in lymphangio-genesis. Mol Biol Cell. 2006;17(2):576-584. (Pubitemid 43191094)
9. Cao R, Ji H, Feng N, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphan-giogenesis and metastasis. Proc Natl Acad Sci USA. 2012;109(39):15894-15899.
10. Kubo H, Cao R, Brakenhielm E, Mäkinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibro-blast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA. 2002;99(13):8868-73. (Pubitemid 34693650)
11. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cradiovasc Med. 2003;13(1):1-7.
12. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999; 144(4):789-801. (Pubitemid 29234556)
13. Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 2001;61(22):8079-8084. (Pubitemid 33091593)
14. Arimoto J, Ikura Y, Suekane T, et al. Expression of LYVE-1 in sinusoidal endothelium is reduced in chronically inflamed human livers. J Gastroen-terol. 2010;45(3):317-325.
15. Frech S, Hörmann K, Riedel F, Götte K. Lymphatic vessel density in correlation to lymph node metastasis in head and neck squamous cell carcinoma. Anticancer Res. 2009;29(5):1675-1679.
16. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymp-hangiogenesis. Trends Immunol. 2001;22(6):317-321. (Pubitemid 32675245)
17. Gale N, Prevo R, Espinosa J, et al. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol Cell Biol. 2007;27(2):595-604. (Pubitemid 46080127)
18. Boensch C, Huang SS, Huang JS. Cell surface retention sequence binding protein-1 interacts with the v-sis gene product and platelet-derived growth factor ß-type receptor in simian sarcoma virus-transformed cells. J Biol Chem. 1999; 274(15):10582-10589.
19. Huang SS, Tang FM, Huang YH, et al. Cloning, expression, characterization, and role in auto-crine cell growth of cell-surface retention sequence binding protein-1. J Biol Chem. 2003; 278(44):43855-43869. (Pubitemid 37346014)
20. Huang SS, Liu IH, Smith T, Shah MR, Johnson FE, Huang JS. CRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels. FEBS Lett. 2006;580(26):6259-6268. (Pubitemid 44666810)
21. Luong MX, Tam J, Lin Q, et al. Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice. J Cell Physiol. 2009;219(2):430-437.
22. Jalkanen ST, Bargatze RF, Herron LR, Butcher EC. A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol. 1986;16(10):1195-1202. (Pubitemid 17171524)
23. Jones M, Tussey L, Athanasou N, Jackson DG. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as para-crine regulators of fibroblast-growth factor action. J Biol Chem. 2000;275(11):7964-7974. (Pubitemid 30159706)
24. van Royen N, Voskuil M, Hoefer I, et al. CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization. Circulation. 2004;109(13):1647-1652. (Pubitemid 38451722)
25. Roghani M, Moscatelli D: Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfatemediated mechanisms. J Biol Chem. 1992;267(31):22156-22162.
26. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF2) activity and inhibits FGF2 dimerization. Blood. 1998;91(9):3289-3299. (Pubitemid 28193879)
27. Aidoudi S, Bujakowska K, Kieffer N, Bikfalvi A. The CXC-chemokine CXCL4 interacts with integ-rins implicated in angiogenesis. PLoS One. 2008; 3(7):e2657.
28. PerkinElmer LaAS. A practical guide to working with AlphaScreen 2004. http://las.perkinElmer.com/content/Manuals/GDE-AlphaScreenPrac-ticalGuide.pdf.
29. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduc-tion. Mol Cell Biol. 1996;16(3):977-989. (Pubitemid 26061669)
30. Rusnati M, Dell'Era P, Urbinati C, et al. A distinct basic fibroblast growth factor (FGF2)/FGF receptor interaction distinguishes urokinase-type plas-minogen activator induction from mitogenicity in endothelial cells. Mol Biol Cell. 1996;7(3):369-381. (Pubitemid 26090891)
31. Bikfalvi A. Angiogenesis: health and disease. Ann Oncol. 2006;17(Suppl 10):65-70.
32. Cao R, Lim S, Ji H, et al. Mouse corneal lymp-hangiogenesis model. Nat Protoc. 2011;6(6):817-826.
33. Regenfuss B, Onderka J, Bock F, Hos D, Maruyama K, Cursiefen C. Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol. 2010;177(1):501-510.
34. Johnson LA, Prevo R, Clasper S, Jackson DG. Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1. J Biol Chem. 2007;282(46):33671-33680. (Pubitemid 350159526)
35. The Human Protein Atlas version 8. 0. www.proteinatlas.org, version 10. 0. Atlas updated: 2012;9-12.
36. Cao R, Björndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004; 6(4):333-345. (Pubitemid 39361435)
37. Facchiano A, De Marchis F, Turchetti E, et al. The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. J Cell Sci. 2000;113(16):2855-2863.
38. DiGabriele AD, Lax I, Chen DI, et al. Structure of a heparin-linked biologically active dimer of fibro-blast growth factor. Nature. 1998;393(6687):812-807.
39. Goldfarb M. Signaling by fibroblast growth factors: the inside story. Sci STKE. 2001;30(106): pe37.
40. Gleizes PE, Noaillac-Depeyre J, Amalric F, Gas N. Basic fibroblast growth factor (FGF2) in-ternalization through the heparan sulfate proteoglycans- mediated pathway: an ultrastruc-tural approach. Eur J Cell Biol. 1995;66(1):47-59.
41. Citores L, Wesche J, Kolpakova E, Olsnes S. Uptake and intracellular transport of acidic fibroblast growth factor: evidence for free and cytoskeleton-anchored fibroblast growth factor receptors. Mol Biol Cell. 1999;10(11):3835-3848. (Pubitemid 29534029)
42. Tkachenko E, Lutgens E, Stan RV, Simons M. Fibroblast growth factor 2 endocytosis in endo-thelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent mac-ropinocytic pathway. J Cell Sci. 2004;117(Pt 15): 3189-3199. (Pubitemid 39139905)
43. Hou WH, Liu IH, Tsai CC, Johnson FE, Huang SS, Huang JS. CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin. J Cell Sci. 2011;124(8):1231-1244.
44. Murakami M, Nguyen LT, Zhuang ZW, et al. The FGF system has a key role in regulating vascular integrity. J Clin Invest. 2008;118(10):3355-3366.
45. Karsan A, Yee E, Poirier GG, Zhou P, Craig R, Harlan JM. Fibroblast growth factor-2 inhibits en-dothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol. 1997; 151(6):1775-1784. (Pubitemid 27527940)
46. Nakao S, Zandi S, Faez S, Kohno R, Hafezi-Moghadam A. Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as mi-crovalves and immunological hot spots. FASEB J. 2012;26(2):808-817.